Company news

argenx SE news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

June 20, 2025

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

June 10, 2025

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

April 28, 2025

← Newer news releases

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 72 decks. Every deck is listed under its year.